The High Authority of Health has given the green light to using the Moderna vaccine in France. It is the second anti-Covid-19 vaccine to be authorized in France, after that of Pfizer and BioNTech.
After that of Pfizer and BioNTech, it is that of Moderna, which was validated this Friday, January 8, by the High Authority of Health, a few days after the European Health Authority's green light.
The vaccine against Covid-19 developed by Moderna "can be used in people 18 years of age and over, including the elderly because of its effectiveness and overall satisfactory tolerance profile", estimates the Haute Autorité de Santé ( HAS).
This vaccine, which received marketing authorization from the European Union on Wednesday, becomes the second to be used in France after BioNTech-Pfizer, which had the green light from the HAS on December 24.
First deliveries from January
The clinical trial carried out by the American laboratory concluded that it is 94% effective in preventing symptomatic forms of the Covid-19 disease, the health authority recalled. The "vaccine strategy" already announced (starting with the populations most at risk of severe form and those most exposed to the risk of infection) remains valid for this vaccine and adds the HAS's opinion.
The vaccine from the American laboratory can be used "including" in the elderly, it considers. Like the BioNTech / Pfizer vaccine, Moderna's vaccine relies on the administration of two doses. For the latter, a "period of 28 days between the two vaccine doses must be respected", states the HAS, stressing that it is a "minimum threshold".
The first deliveries of the Moderna vaccine "should be made in the coming days," at the latest "second half of January", assured this Friday morning on the BFMTV channel Professor Alain Fischer, the "Mr. vaccines" appointed by the government.
On January 8, France approved Moderna's vaccine while registering 281 new coronavirus deaths up from 277 as suggested by the ministry data.